White Paper:
Looking Ahead: Ophthalmology Clinical Trial Landscape in 2023

Over 2.2 billion people worldwide are estimated to be visually impaired or blind resulting in a global economic burden of approximately US$269 billion, annually. In the U.S., approximately 12 million people aged 40 years and above have vision impairment and the associated economic impact of major vision problems for this group is US$145 billion, annually. Fueled by research in ophthalmology, eye diseases such as cataracts and AMD, previously thought to be irreversible, now have treatment options that can cure or alleviate symptoms.

This white paper will cover:

  • Growth in demand for ophthalmology CRO services
  • Growth in the ophthalmic therapeutic drugs market
  • Ophthalmology research trends